Search Results
Viewing: 361-370 of 403 | All
Article
Skeens Lab Staff
Learn more about principal investigator Micah Skeens, PhD, APRN, FAAN, and her dynamic team in the Skeens Lab.
Meet Our Team
Meet our Laboratory Services team.
News
New Initiative Aims to Improve Diagnosis and Treatment of Children with Solid Tumors Through Molecular Analysis
The National Cancer Institute (NCI), part of the National Institutes of Health, Children’s Oncology Group (COG), and Nationwide Children's Hospital are poised to change the direction of pediatric cancer diagnosis and care. New results from international efforts to characterize pediatric cancers have led to the Molecular Characterization Initiative: a project that aims to collect, analyze, and report clinical molecular data to support COG-affiliated clinicians in choosing the best treatment for each child. This program is part of the NCI Childhood Cancer Data Initiative (CCDI).
News
Nationwide Children's Hospital Breaks Ground for New Main Hospital
Columbus Mayor Michael Coleman joined Nationwide Children’s Hospital officials today at a groundbreaking ceremony for a new 12-floor main hospital building encompassing 720,000 square feet.
Article
Radiation Therapy
This Helping Hand™ goes over the process of radiation therapy and what to expect.
Article
Respiratory Therapy Careers
Nationwide Children’s is hiring Registered Respiratory Therapists for positions in various areas of pediatric care. New graduates are encouraged to apply. Interviews are being offered to current students with pending graduation dates.
Condition
Wilms' Tumor
This Helping Hand™ covers Wilms' tumor, a cancerous tumor of the kidney. It is thought to be caused by abnormal genes. The tumor may occur at any age, but it is most common in children 1 to 5 years of age.
News
Study supports virotherapy as a potential treatment for brain tumors
A new study provides additional evidence of the efficacy of virotherapy for glioblastoma, the most deadly type of brain tumor. The research findings, published Feb. 1, 2022, in Clinical Cancer Research, indicate that an oncolytic herpes simplex virus, G207, appears to boost immune response and that this is associated with better overall survival for patients with glioblastoma.